MedTrace Logo

Biologicals in Management of Intra-Bony Defects

NCT07292870 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-17

No results posted yet for this study

Summary

The aim is of this study is to evaluate and compare the effects (clinical and radiological) of different biomaterials on the repair of bone defects around the teeth. When participating in this study, persons will be scheduled for local surgical intervention of the gums. Under local anaesthesia, the gums will be opened minimally to gain insight into the underlying bone defect. After the bone defect has been made completely free of inflammation, they will be randomly assigned to one of the groups below and the biomaterials for this group will be used to fill the defect around your teeth. The different biomaterials are artificial bone + amelogenin; artificial bone + hyaluronic acid; artificial bone + blood preparation (L-PRF) or blood preparation alone.

Then the gums will be closed again with a suture and they will receive the necessary instructions regarding the procedure.

Conditions

  • Intra-bony Pockets
  • Periodontitis

Interventions

BIOLOGICAL

Minimally invasive surgical treatment of the intra-bony defects

A surgical procedure is performed under local anaesthesia in which one of the biomaterials will be used to fill the intra-bony defect.

BIOLOGICAL

Use of the xenograft Bio-Oss® Collagen during the surgery

The clinician will use Bio-Oss® Collagen as adjuvant in the surgical treatment of the intra-bony defects in conjunction with minimally invasive surgery

BIOLOGICAL

Use of enamel matrix derivative (Emdogain®)

The clinician will use Enamel matrix derivative (Emdogain®) as adjuvant in the surgical treatment of the intra-bony defects in conjunction with minimally invasive surgery.

BIOLOGICAL

Use of hyaluronic acid (REGENFAST®)

The clinician will use hyaluronic acid (REGENFAST®) as adjuvant in the surgical treatment of the intra-bony defects in conjunction with minimally invasive surgery

BIOLOGICAL

use of the blood derivative L-PRF (leukocyte and platelet rich fibrin)

The clinician will use L-PRF as adjuvant in the surgical treatment of the intra-bony defects in conjunction with minimally invasive surgery.

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Ana Castro, Professor · UZLeuven, department of Oral Health Sciences, Periodontology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-08
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07292870 on ClinicalTrials.gov